Products, suppliers and subsidiaries before 2018

analysisIn its 2002 annual report Exactech said it bought about 69%, 59% and 69% of its externally sourced components from its top three manufacturers over three years and had no supply contracts with them, buying by purchase order. By 2016 it had built up its own manufacturing, typically the final machining of semi-finished metal and polyethylene components; its top three suppliers then accounted for about 20% to 24% of outside components, and it still had no supply contracts with most manufacturers. It warned that some suppliers relied on a single source for raw materials, and it distributed other companies' products under an exclusive agreement with Tecres S.p.A. and non-exclusive agreements with RTI Surgical and Biomatlante. ^{1 2 3}

analysisExactech's subsidiary lists name Exactech International Corporation of Florida, Exactech Medical (Shanghai), Exactech Taiwan, Exactech (UK) and Exactech KK of Tokyo and, in the earlier list, Altiva Corporation of Delaware; the 2013 list adds Exactech U.S., Exactech International Operations, Exactech France, Exactech Deutschland and Exactech Iberica. According to the 2018 merger proxy the company sold in the United States through Exactech U.S., Inc. and ran international development, sales and distribution through Exactech International Operations, AG. ^{1 2 3}

analysisIn January 2015 Exactech bought 100% of BlueOrtho SAS of Grenoble, developer of its ExactechGPS navigation system, for up to 10 million euros, 2 million at closing and up to 8 million in earnouts; BlueOrtho had been founded by its president Anthony Boyer, orthopaedic surgeon James Stiehl and Stephane Lavallee. The merger proxy recounts a $150 million revolving credit facility from a J.P. Morgan Chase syndicate in December 2015, the purchase of its Australian distributor in February 2016 and of 24.55% of Orthopedic Designs North America in October 2016, and in 2017 the sale of its spine business, of its majority stake in Exactech (Taiwan) and of its China subsidiary. ^{4 3}

analysisTaiwanese sources describe the buyer of the Taiwan subsidiary: according to a company-information site, BioGend Therapeutics bought 81% of 美精技股份有限公司, set up by Exactech to develop cartilage-repair technology, on July 31, 2017 and absorbed it by merger on December 31, 2017, and a 2019 news report listed "美精技 (Exactech)" among BioGend's main shareholders with about 5%. Separately, an offshore-leaks database lists an EXACTECH INTERNATIONAL, INC. incorporated in Barbados in January 1999, with CITCO's Barbados company as intermediary and David Petty, William Petty, Timothy Seese and Gary Miller as directors, closed in October 2003; the data do not state its owner or purpose and its inclusion does not indicate wrongdoing. ^{5 3 6 7 8}

analysisFDA's enforcement data record a class II recall that Exactech began on June 15, 2012 of Equinoxe plates and screws and Octane-C fusion devices, labelled with a ten-year shelf life although their packaging was qualified for five, covering 54,877 units, and a class II recall begun on September 19, 2017 of Optetrak offset tibial trays and screws because of a design incompatibility with a constrained insert. ¹